ECSP20018487A - Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre - Google Patents

Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Info

Publication number
ECSP20018487A
ECSP20018487A ECSENADI202018487A ECDI202018487A ECSP20018487A EC SP20018487 A ECSP20018487 A EC SP20018487A EC SENADI202018487 A ECSENADI202018487 A EC SENADI202018487A EC DI202018487 A ECDI202018487 A EC DI202018487A EC SP20018487 A ECSP20018487 A EC SP20018487A
Authority
EC
Ecuador
Prior art keywords
treatment
pyruvate kinase
blood disorders
kinase activators
activators
Prior art date
Application number
ECSENADI202018487A
Other languages
English (en)
Inventor
Zhenwei Cai
Zhihua Sui
Tao Liu
Anil Padyana
Giovanni Cianchetta
Jingjing Ji
Dawei Cui
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of ECSP20018487A publication Critical patent/ECSP20018487A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos que activan la piruvato quinasa, composiciones farmacéuticas y métodos para usarlos. Estos compuestos están representados por la fórmula (I), donde R1, R2, Ra, Rb, Rj, Rk y Q son como se los define en la presente.
ECSENADI202018487A 2017-08-15 2020-03-13 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre ECSP20018487A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673533P 2018-05-18 2018-05-18
US201862673526P 2018-05-18 2018-05-18
EC2018000128 2018-08-15

Publications (1)

Publication Number Publication Date
ECSP20018487A true ECSP20018487A (es) 2020-05-29

Family

ID=63524352

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202018487A ECSP20018487A (es) 2017-08-15 2020-03-13 Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre

Country Status (34)

Country Link
US (8) US11590132B2 (es)
EP (4) EP4026838A1 (es)
JP (5) JP7275107B2 (es)
KR (3) KR102717594B1 (es)
CN (3) CN117186119A (es)
AU (4) AU2018316588B2 (es)
BR (1) BR112020003254A2 (es)
CA (1) CA3072455A1 (es)
CL (1) CL2020000375A1 (es)
CO (2) CO2020002961A2 (es)
CR (1) CR20200123A (es)
CY (1) CY1124953T1 (es)
DK (2) DK3668513T3 (es)
EC (1) ECSP20018487A (es)
ES (3) ES2966825T3 (es)
FI (1) FI3668512T3 (es)
HR (2) HRP20220039T1 (es)
HU (2) HUE057178T2 (es)
IL (3) IL272599B (es)
LT (2) LT3668512T (es)
MD (1) MD3668513T2 (es)
MX (2) MX2020001832A (es)
MY (1) MY204421A (es)
PE (1) PE20200724A1 (es)
PH (1) PH12020500343B1 (es)
PL (2) PL3668512T3 (es)
PT (2) PT3668513T (es)
RS (2) RS62871B1 (es)
SG (2) SG11202001262QA (es)
SI (2) SI3668512T1 (es)
SM (2) SMT202300146T1 (es)
TW (3) TWI796353B (es)
UA (1) UA126292C2 (es)
WO (3) WO2019035865A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3448859T (pt) 2017-03-20 2019-10-25 Forma Therapeutics Inc Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
SG11202001262QA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in treating blood disorders
US12233063B2 (en) 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
SG11202108744WA (en) * 2019-02-13 2021-09-29 Agios Pharmaceuticals Inc Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders
WO2020262419A1 (ja) * 2019-06-26 2020-12-30 日産化学株式会社 電荷輸送性ワニス
CN114615977B (zh) 2019-09-19 2025-01-14 诺沃挪第克健康护理股份公司 丙酮酸激酶r(pkr)活化组合物
EP4185293A4 (en) * 2020-07-21 2025-01-15 The Regents of The University of Michigan COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CA3231728A1 (en) * 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
IL312679A (en) * 2021-11-16 2024-07-01 Agios Pharmaceuticals Inc Compounds for the treatment of anemia associated with MDS and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
EP4671102A1 (en) 2023-03-28 2025-12-31 Honda Motor Co., Ltd. METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS
TW202509043A (zh) 2023-05-15 2025-03-01 美商阿吉歐斯製藥公司 ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式
CN121443584A (zh) * 2023-07-05 2026-01-30 安吉奥斯医药品有限公司 丙酮酸激酶活化剂的合成
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
AU6388900A (en) 1999-07-30 2001-02-19 Abbott Gmbh & Co. Kg 2-pyrazolin-5-ones
BR0013694A (pt) 1999-09-04 2002-05-21 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, e, uso de um composto
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR20110033299A (ko) * 2008-07-23 2011-03-30 버텍스 파마슈티칼스 인코포레이티드 트리-사이클릭 피라졸로피리딘 키나제 억제제
WO2010025202A1 (en) * 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
JP5632379B2 (ja) * 2008-10-09 2014-11-26 アメリカ合衆国 ヒトピルビン酸キナーゼ活性化剤
EP2417123A2 (en) * 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CR20170071A (es) 2009-06-29 2017-03-28 Agios Pharmaceuticals Inc Compuestos terapeuticos y composiciones
CA2797694A1 (en) 2010-04-29 2011-11-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Activators of human pyruvate kinase
JP5886310B2 (ja) 2010-12-06 2016-03-16 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
ME03074B (me) * 2011-05-03 2019-01-20 Agios Pharmaceuticals Inc Akтivatori piruvat kinaze za upotrebu u terapiji
CA2834692A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
EP3372230B1 (en) 2011-05-03 2020-08-12 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
CN103930422A (zh) * 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
WO2014074848A1 (en) 2012-11-08 2014-05-15 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions and their use as pkm2 modulators
EP2951181A1 (en) * 2013-01-30 2015-12-09 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
HRP20220195T1 (hr) 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
SG11202001262QA (en) 2017-08-15 2020-03-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in treating blood disorders
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
KR20200041942A (ko) 2017-08-15 2020-04-22 애브비 인코포레이티드 거대환식 mcl-1 저해제 및 이의 용도
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
SG11202108744WA (en) * 2019-02-13 2021-09-29 Agios Pharmaceuticals Inc Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Also Published As

Publication number Publication date
US20220233541A1 (en) 2022-07-28
US11590132B2 (en) 2023-02-28
CR20200123A (es) 2020-06-29
EP3668513A1 (en) 2020-06-24
HUE057178T2 (hu) 2022-04-28
RS62871B1 (sr) 2022-02-28
ES2966825T3 (es) 2024-04-24
JP7301040B2 (ja) 2023-06-30
IL272597B (en) 2022-06-01
WO2019035863A8 (en) 2019-03-28
TWI796353B (zh) 2023-03-21
KR102717594B1 (ko) 2024-10-14
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
CA3071993A1 (en) 2019-02-21
PT3668512T (pt) 2023-05-22
US20230226055A1 (en) 2023-07-20
SMT202200023T1 (it) 2022-03-21
TWI790271B (zh) 2023-01-21
WO2019035863A1 (en) 2019-02-21
JP7275107B2 (ja) 2023-05-17
US20220395503A1 (en) 2022-12-15
JP2023027276A (ja) 2023-03-01
WO2019035864A1 (en) 2019-02-21
RU2020110573A3 (es) 2021-12-24
UA126292C2 (uk) 2022-09-14
EP4026838A1 (en) 2022-07-13
HRP20230452T1 (hr) 2023-07-21
KR20200054200A (ko) 2020-05-19
CO2020002959A2 (es) 2020-04-13
JP7530453B2 (ja) 2024-08-07
TW201919631A (zh) 2019-06-01
TW202323258A (zh) 2023-06-16
SG11202001262QA (en) 2020-03-30
AU2018316587B2 (en) 2023-05-11
CN111032045B (zh) 2023-08-15
PH12020500343B1 (en) 2024-02-21
US11957680B2 (en) 2024-04-16
EP3668512A1 (en) 2020-06-24
CN111032046B (zh) 2023-09-26
US20250144093A1 (en) 2025-05-08
US11364240B2 (en) 2022-06-21
RS64221B1 (sr) 2023-06-30
SI3668513T1 (sl) 2022-04-29
HRP20220039T1 (hr) 2022-04-15
CL2020000375A1 (es) 2020-12-11
AU2024205818A1 (en) 2024-09-05
PL3668512T3 (pl) 2023-06-19
DK3668513T3 (da) 2022-01-10
CN117186119A (zh) 2023-12-08
JP2020531432A (ja) 2020-11-05
EP3668881B1 (en) 2023-10-04
US11872225B2 (en) 2024-01-16
JP2023052478A (ja) 2023-04-11
ES2944545T3 (es) 2023-06-22
HUE061910T2 (hu) 2023-08-28
DK3668512T3 (da) 2023-05-22
CO2020002961A2 (es) 2020-04-13
KR20200054199A (ko) 2020-05-19
KR102642408B1 (ko) 2024-02-28
KR20230127364A (ko) 2023-08-31
MX2020001833A (es) 2020-07-22
US20200206225A1 (en) 2020-07-02
MY204421A (en) 2024-08-28
CA3072455A1 (en) 2019-02-21
US11464775B2 (en) 2022-10-11
WO2019035864A8 (en) 2019-03-28
AU2018316588B2 (en) 2023-02-02
IL292530A (en) 2022-06-01
SG11202001353PA (en) 2020-03-30
SMT202300146T1 (it) 2023-07-20
US12133853B2 (en) 2024-11-05
JP2024147805A (ja) 2024-10-16
CY1124953T1 (el) 2023-01-05
IL272599A (en) 2020-03-31
AU2023202772B2 (en) 2024-05-16
SI3668512T1 (sl) 2023-06-30
BR112020003254A2 (pt) 2020-10-27
FI3668512T3 (fi) 2023-05-12
PH12020500343A1 (en) 2021-02-08
US20200207785A1 (en) 2020-07-02
AU2018316588A1 (en) 2020-02-20
US20210130371A1 (en) 2021-05-06
PE20200724A1 (es) 2020-07-21
EP3668513B1 (en) 2021-11-10
US11040036B2 (en) 2021-06-22
WO2019035865A8 (en) 2019-03-28
BR112020003262A2 (pt) 2020-09-01
LT3668512T (lt) 2023-06-12
IL292530B2 (en) 2023-06-01
JP2020531443A (ja) 2020-11-05
ES2905100T3 (es) 2022-04-07
WO2019035865A1 (en) 2019-02-21
CN111032046A (zh) 2020-04-17
EP3668512B1 (en) 2023-02-15
IL272599B (en) 2022-08-01
RU2020110573A (ru) 2021-09-16
TW201920203A (zh) 2019-06-01
IL272597A (en) 2020-03-31
MD3668513T2 (ro) 2022-04-30
AU2018316587A1 (en) 2020-02-20
MX2020001832A (es) 2020-07-22
AU2023202772A1 (en) 2023-05-18
US20210077490A1 (en) 2021-03-18
EP3668881A1 (en) 2020-06-24
PL3668513T3 (pl) 2022-03-21
LT3668513T (lt) 2022-03-25
KR102764124B1 (ko) 2025-02-05
CN111032045A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
UY38076A (es) Derivados de tetrahidroquinazolina útiles como agentes anticáncer
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
GT201700189A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
MX2017014375A (es) Moduladores del ccr2.
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2015003037A1 (es) Derivados de triazina
CU20180044A7 (es) Derivados novedosos de diamino piridina
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores